# Transient Mood Elevation Without a Manic Switch: Goldenseal-Augmented Oral Glutamatergic Regimen in Bipolar Depression With Comorbid Obsessive-Compulsive Disorder (OCD)

**Authors:** Ngo Cheung

PMC · DOI: 10.7759/cureus.104209 · Cureus · 2026-02-24

## TL;DR

A 32-year-old man with bipolar depression and OCD experienced temporary mood improvement using a regimen including goldenseal and dextromethorphan, without a manic switch.

## Contribution

This case suggests that goldenseal, a CYP2D6 inhibitor, may prolong the effects of oral dextromethorphan in bipolar depression.

## Key findings

- The patient experienced transient mood elevation and improved work performance after adding goldenseal.
- Improvement faded when goldenseal was stopped and returned when it was restarted.
- No hypomanic symptoms or side effects were observed during the treatment period.

## Abstract

Treating bipolar depression that comes with obsessive, looping thoughts can be tricky because standard antidepressants often help only a little and can sometimes push the mood too high. In this report, we followed a 32-year-old man whose low mood and health-related ruminations lingered despite mood stabilisers (valproate, low-dose aripiprazole, pregabalin, and Deanxit). Hoping to copy some of ketamine's brain-circuit effects, he tried an over-the-counter mix of dextromethorphan, piracetam, and L-glutamine; the result was modest at best. Ten days after he added 600 mg of the herbal CYP2D6 inhibitor goldenseal, thought to slow the breakdown of dextromethorphan, he reported a clear lift in energy, mood, and work performance, with no signs of hypomania; the improvement faded when he stopped the herb and returned when he restarted it, and he had no side effects. Although this single experience cannot show cause and effect, it hints that short courses of a well-standardised botanical CYP2D6 inhibitor might prolong the benefit some patients get from oral dextromethorphan-based combinations, an idea that would need careful study, including drug-level monitoring and checks for mood switches.

## Linked entities

- **Proteins:** CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene))
- **Chemicals:** dextromethorphan (PubChem CID 5360696), piracetam (PubChem CID 4843), L-glutamine (PubChem CID 5961), valproate (PubChem CID 3549980), aripiprazole (PubChem CID 60795), pregabalin (PubChem CID 4715169), Deanxit (PubChem CID 6438809)
- **Diseases:** bipolar depression (MONDO:0004985), obsessive-compulsive disorder (MONDO:0008114)

## Full-text entities

- **Genes:** CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}
- **Diseases:** gastrointestinal or hepatic (MESH:D005767), ADHD (MESH:D001289), binge eating (MESH:D002032), toxicity (MESH:D064420), GAD-7 (MESH:C000726808), carcinogenic (MESH:D011230), hypomania (MESH:D000087122), impulsive (MESH:D007174), OCD (MESH:D009771), depression (MESH:D003866), Bipolar disorder (MESH:D001714), irritability (MESH:D001523), Mood and Anxiety (MESH:D001007), major depression (MESH:D003865), neurotransmitter deficits (MESH:D009461)
- **Chemicals:** Ritalin (MESH:D008774), lamotrigine (MESH:D000077213), propranolol (MESH:D011433), Valproate (MESH:D014635), lurasidone (MESH:D000069056), pregabalin (MESH:D000069583), Cheung Glutamatergic Regimen (-), AMPA (MESH:D018350), olanzapine (MESH:D000077152), berberine (MESH:D001599), Quetiapine (MESH:D000069348), piracetam (MESH:D010889), L-glutamine (MESH:D005973), fluoxetine (MESH:D005473), Deanxit (MESH:C000851), aripiprazole (MESH:D000068180), clonazepam (MESH:D002998), bupropion (MESH:D016642), alprazolam (MESH:D000525), lemborexant (MESH:C000634104), Alkaloid (MESH:D000470), glutamate (MESH:D018698), NMDA (MESH:D016202), risperidone (MESH:D018967), Efexor (MESH:D000069470), hydrastine (MESH:C013024), lithium (MESH:D008094), dextromethorphan (MESH:D003915)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12933005/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12933005/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12933005/full.md

---
Source: https://tomesphere.com/paper/PMC12933005